Pharmaceutical compounds in aquatic environment in China: locally screening and environmental risk assessment
Yongshan CHEN , Xiuping XI , Gang YU , Qiming CAO , Bin WANG , François VINCE , Youwei HONG
Front. Environ. Sci. Eng. ›› 2015, Vol. 9 ›› Issue (3) : 394 -401.
Pharmaceutical compounds in aquatic environment in China: locally screening and environmental risk assessment
An environmental risk assessment was performed for pharmaceutical compounds present in the aquatic environment of China. Predicted environmental concentration (PEC) of the compounds were calculated according to European Medicines Evaluation Agency (EMEA) guidelines. Available ecotoxicological data compromised by applying a very conservative assessment factor (AF) were employed to calculate the predicted no-effect concentration (PNEC). The screening principle and the risk assessment were based on risk quotient (RQ), which derived from the PEC and related PNEC values. PEC results indicated that all the compounds except sulfadimethoxine and levocarnitine, should carry out phase II risk assessment in EMEA guideline. RQ values suggested that more than 36 pharmaceuticals may be imposed health threats to the aquatic environment; especially the antibiotic therapeutic class including amoxicillin, sulfasalazine, trimethoprim, oxytetracycline and erythromycin showed high RQ values. These substances with high RQ value (RQ≥1) were regarded as top-priority pharmaceuticals for control in the aquatic environment of China. However, the antibiotic substances which had low risk quotient (RQ <1), should be reassessed by its potentially induced resistance under low concentration in future.
pharmaceuticals / aquatic environment / risk assessment / aquatic toxicity / risk quotient
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
EMEA. Discussion paper on environmental risk assessment of non-genetically modified organism (non-GMO) containing medicinal products for human use. CPMP/SWP/4447/00 draft corr. The European Agency for the Evaluation of Medicinal Products, 2001 |
| [14] |
EMEA. Guideline on the environmental risk assessment of medicinal products for human use. CHMP/SWP/4470/00 draft. The European Agency for Evaluation of Medidicinal Products- Pre-Authorisation Evaluation of Medicines for Human Use (Committee for medicinal Products for Human Use), 2005 |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
WHO Collaborating Centre, WHO Collaborating Centre for Drug Statistics Methodology, Oslo. |
| [33] |
China Medicine Economic Information Net (CMEIN). Chinese Medical Statistical Yearbook (2006–2007). Beijing: China Medicine Economic Information Net, 2007 |
| [34] |
MistraPharma Wiki Database |
| [35] |
Veterinary Substances DataBase (VSDB) |
| [36] |
|
| [37] |
|
| [38] |
Estimation Programs Interface (EPI) SuiteTM was developed by the US Environmental Protection Agency’s Office of Pollution Prevention |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
Higher Education Press and Springer-Verlag Berlin Heidelberg
/
| 〈 |
|
〉 |